Company intelligence / Profile preview
Allist Pharmaceuticals
Shanghai, Shanghai, China
- Ownership
- Public · 688578
- Employees
- ~1417
- Development stage
- Other
01
Overview
Allist has successfully launched furmonertinib for NSCLC (EGFR mutations) with strong sales in China and received FDA Breakthrough Therapy Designation for EGFR exon 20 insertions. Glecirasib (KRAS G12C inhibitor) received first marketing approval in China in May 2025. Multiple pipeline assets are in registrational/late-stage trials for oncology, primarily lung cancer[5][9].
- Therapeutic areas
- EndocrinologyInfectious DiseasesGastroenterologyCardiovascularOncology
- Modalities
- Small moleculeLiposomal drugBiologic
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Jacobio Pharma (KRAS G12C, SHP2 inhibitors)[2][8]Abbisko Therapeutics (PD-L1/EGFR therapies)[5]Global Biotech Co. (drug development)[6]Local Chinese research institutes (clinical trials)[6]
Beyond the preview
Go deeper on Allist Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allist Pharmaceuticals.